NCT07118579
Effects of Remimazolam and Ciprofol TIVA on PRAE in Pediatric Tonsillectomy and Adenoidectomy
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 3 versions: 3 with changes below. See every version on ClinicalTrials.gov ↗
Notable Eligibility criteria expanded, about 11 words Show 5 more changesShow less
- Trial completed
- Primary completion date changed from estimate of Aug 2026 to Jun 30, 2026
- Enrollment target: estimated 114 to confirmed 111
- Secondary endpoints: details revised at 2 of 6 entries
- Site details revised
Notable Trial status: Not Yet Recruiting to Recruitingv2 Show 4 more changesShow less
- Primary and study completion dates: Dec 2025 to Aug 2026
- Start date changed from estimate of Aug 2025 to Sep 23, 2025
- Secondary endpoints revised (6)
- Site details revised
- Study First Submitted
- Notable: the plan changed
Endpoints
Primary
The incidence of perioperative respiratory adverse events
Timeframe: 5days
Secondary (6)
Anesthesia duration
Emergence time
Extubation time
PACU stay duration
The modified Aldrete score
Show 1 moreShow less
doses of drugs
Arms and interventions
Propofol groupActive comparator
Anesthesia induction (2-3 mg/kg) + Anesthesia maintenance (6-10 mg/kg/h)
Remimazolam groupExperimental
Anesthesia induction (0.3-0.5 mg/kg) + Anesthesia maintenance (1-3 mg/kg/h)
Ciprofol groupExperimental
Anesthesia induction (0.4-0.5 mg/kg) + Anesthesia maintenance (0.8-1.2 mg/kg/h)
Drugs: Remimazolam, Propofol, Ciprofol
Sites
1 site in 1 country
- Tongji HospitalWuhan, Hubei, China